<DOC>
	<DOCNO>NCT00834457</DOCNO>
	<brief_summary>Open-label study regimen antiretrovirals treatment AIDS-KS . This study conduct single site , Parirenyatwa Hospital KS Clinic . Step 1 conducted determine extent clinical resolution AIDS-KS disease response treatment antiretroviral therapy investigate whether clinical resolution KS associate suppression KSHV replication . Step 2 developed evaluate clinical , immunological , virological effect switch twice-daily all-nucleoside reverse transcriptase inhibitor ( NRTI ) antiretroviral regimen once-daily regimen 2 NRTIs plus ritonavir-boosted protease inhibitor person AIDS-KS good virologic suppression NRTI regimen . Step 3 included evaluate clinical , immunological , virological effect intensification ritonavir-boosted protease inhibitor person AIDS-KS virological failure NRTI regimen .</brief_summary>
	<brief_title>A Pilot Study Of Effects Highly Active Antiretroviral Therapy Kaposi 's Sarcoma Zimbabwe</brief_title>
	<detailed_description>To identify factor associate successful treatment KS antiretroviral therapy determine highly active antiretroviral therapy improve survival quality life person AIDS-KS Zimbabwe . A secondary objective investigate durability HIV-1 suppression combination ABC/3TC/ZDV person infect HIV-1 subtype C evaluate timing characteristic mutation HIV-1 reverse transcriptase subject fail achieve , maintain suppression HIV-1 replication treatment ABC/3TC/ZDV . An important objective ass adherence simplify antiretroviral regimen resource-limited setting . The study evaluate clinical , immunological , virological effect switch twice-daily all-nucleoside reverse transcriptase inhibitor ( NRTI ) antiretroviral regimen once-daily regimen 2 NRTIs plus ritonavir-boosted protease inhibitor person AIDS-KS good virologic suppression ABC/3TC/ZDV ( see ) .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Completion least 96 week treatment ABC/3TC/ZDV protocol Step 1 . Currently receive ABC/3TC/ZDV Step 1/initial openlabel allNRTI phase study . Plasma HIV1 RNA &lt; 400 copies/mL recent plasma HIV1 RNA perform within 4 week Step 2 entry . Willing potentially switch new antiretroviral regimen . In opinion site investigator currently clinical evidence active KS disease . Exclusion Criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>AIDS-related Kaposi 's sarcoma</keyword>
	<keyword>antiretroviral therapy</keyword>
</DOC>